FLT3 inhibitors: clinical potential in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in as few as 15%–40% of cases. Tremendous improvements in AML prognostication arose from a comprehensive analysis of leukemia cell genomes. Among normal karyotype AML cases, mutations in the FLT3 gene are the ones m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hospital, Marie-Anne, Green, Alexa S, Maciel, Thiago T, Moura, Ivan C, Leung, Anskar Y, Bouscary, Didier, Tamburini, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304990/
https://www.ncbi.nlm.nih.gov/pubmed/28223820
http://dx.doi.org/10.2147/OTT.S103790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304990/
https://www.ncbi.nlm.nih.gov/pubmed/28223820
http://dx.doi.org/10.2147/OTT.S103790

Ejemplares similares